SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently caught between conflicting macroeconomic pressures as investors weigh potential peace deal headlines against geopolitical instability and shifting institutional capital flows. The community remains deeply polarized, with active debates centered on whether recent price action signifies a long-term decoupling from traditional equities or a precarious bull trap ahead of a potential liquidity squeeze.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors debate the impact of newly released joint SEC and CFTC guidance classifying the asset as a digital commodity rather than a security. While the community is actively discussing the potential for institutional adoption and the progress of the Clarity Act, sentiments remain polarized due to ongoing price volatility and frustrations over historical performance compared to broader market trends.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing significant community division, with long-term holders debating whether to continue accumulating during the current downturn or abandon the project due to a lack of clear utility and missed price targets. Conversations are dominated by frustration over recent market performance, skepticism toward the development team's transparency, and contrasting hopes that upcoming news cycles or macroeconomic shifts will eventually spark a recovery.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is seeing intense momentum as it approaches a key psychological resistance level, driven by community excitement over new AI-agent utility and upcoming ecosystem developments. While some traders are locking in profits from recent rallies, a vocal base of investors remains aggressively bullish, viewing the current market cap as undervalued and holding firm in anticipation of a wider breakout.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently seeing heightened market activity as institutional investors pivot toward digital assets following major regulatory developments that classify key cryptocurrencies as digital commodities. The community is actively debating the project's long-term utility in decentralized finance and AI infrastructure, while analysts closely monitor institutional ETF flows and potential resistance levels amid broader macroeconomic volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is currently reeling from intense volatility driven by escalating geopolitical tensions in the Middle East and a barrage of conflicting headlines regarding potential ceasefires and military operations. Market participants are actively debating the long-term impact of rising energy costs and supply chain disruptions while expressing deep division over the administration's handling of the conflict and its influence on global market stability.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Community sentiment regarding the asset is currently polarized, with many investors debating the impact of upcoming ETF filings and strategic ecosystem partnerships against ongoing frustrations with price performance and leadership. While some remain bullish on future growth, there is significant chatter about native meme coins on the Cronos blockchain and a prevailing sense of impatience for clearer catalysts to drive volume.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is seeing significant attention as investors react to treasury-focused initiatives from firms like Eightco and Maison Solutions, which are positioning the token as a core asset for AI-driven digital identity. The community remains deeply divided, with bulls highlighting the long-term potential of proof-of-humanity technology while others express skepticism regarding tokenomics and volatility.

WorldFinancial

World Liberty Financial (WLFI) is drawing significant investor attention as market participants debate its long-term viability amid congressional inquiries into its foreign investment deals and ownership structure. While some investors view the current price action as a high-conviction buying opportunity supported by institutional interest and upcoming product milestones, others remain skeptical, citing concerns over insider control, token lock-ups, and the potential for a sell-the-news event during upcoming forums.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is currently capturing community attention as investors debate the potential of its high-throughput blockchain infrastructure despite significant recent price volatility. While some participants express frustration over ongoing sell-offs and perceived lack of transparency, others are actively accumulating shares, viewing the current market conditions as a strategic opportunity to build long-term positions.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul><p>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.</p><p>Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.</p><p>The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.</p><h2 class="st-heading-2">Analyst Takeaway</h2><p>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.</p><p>The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.</p><h2 class="st-heading-2">About Vyondys And Amondys</h2><p>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.</p><p>While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.</p><p>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.</p><h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2><p>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Equity

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 


Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer

Oppenheimer reiterated an "outperform" rating and set a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday...

Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions with the U.S. Food and Drug...

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

KROS: Is the Discount Book Value a Value Trap?

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.

KROS Stock: What to Know About Rinvatercept in DMD

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.

<ul class="summary-bullets"><li>Sarepta is looking to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</li><li>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</li></ul><p>Shares of Sarepta Therapeutics, Inc. (SRPT) edged up nearly 1.5% on Monday after the company said that screening and enrollment are underway in a cohort of its study, aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>Data from the cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks of acute liver injury and acute liver failure associated with Elevidys in DMD patients who cannot walk.</p><h2 class="st-heading-2">Gene Therapy Study Details</h2><p>Sarepta is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-screening-and-enrollment-are-underway-endeavor">looking</a> to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</p><p>Patients enrolled in the cohort will be administered peri-infusion sirolimus 14 days before Elevidys administration and will continue to receive it for 12 weeks after Elevidys, the company said.</p><p>Elevidys is the only approved gene therapy for Duchenne, a severe, progressive genetic muscle-wasting disease, primarily affecting young boys.</p><p>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">Street Consensus</h2><p>Last week, Mizuho raised the firm's price target on Sarepta to $31 from $26 and kept an ‘Outperform’ rating on the shares, while Citi raised the its price target on Sarepta to $9 from $8 and kept a ‘Sell’ rating on the shares.</p><p>According to data from Koyfin, the average 12-month price target on the stock is $20.61, representing a potential upside of about 24% from current trading levels, as of the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen nearly 84% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-halts-v3-supercharger-production-in-new-york/cZ3PEpcRIQb">Tesla Halts V3 Supercharger Production In New York In Favor Of Faster, Rival EV-Compatible Variant</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc